Teva Pharmaceutical Industries Ltd. said global sales of multiple sclerosis drug Copaxone grew to a record $542 million in the first quarter, up 35% from last year.

The company released the sales figures in conjunction with the announcement of Sanofi-aventis group's financial results. Pursuant to an agreement with Sanofi-aventis, Teva assumed responsibility for distribution of Copaxone in the U.S. and Canada as of April 1, 2008.................

For the full report please go to MSRC: MS Research News : Drugs : Disease Modifying Drugs : Disease Modifying Drugs Ongoing News : COPAXONE® Ongoing News - http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1903